Jingxin Li

InstitutionJiangsu Province Center for Disease Control and Prevention
AddressNanjing
Jiangsu
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 6 Covid-19 publications, with a maximum of 2 publications in April 2021
    All Publications
    Bar chart showing 94 publications over 12 distinct years, with a maximum of 19 publications in 2016
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Wang X, Yang H, Hong L, Wu N, Yuan E, Luo Y, Cheng L, Hu C, Lei Y, Shu H, Feng X, Jiang Z, Wu Y, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Chen L, Li H, Zeng H, Zhao D, Zhu F, Shen X, Zeng J. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021 04 24; 6(1):165. PMID: 33895786.
      Citations: 16     Translation:Humans
    2. Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, Ji R, Lin M, Zhu Z, Türeci Ö, Lagkadinou E, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Sahin U, Zhu L, Zhu F. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070. PMID: 33888900.
      Citations: 19     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    3. Zhao D, Xu W, Zhang X, Wang X, Ge Y, Yuan E, Xiong Y, Wu S, Li S, Wu N, Tian T, Feng X, Shu H, Lang P, Li J, Zhu F, Shen X, Li H, Li P, Zeng J. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2. Protein Cell. 2021 09; 12(9):734-740. PMID: 33770364.
      Citations: 3     Fields:    Translation:Humans
    4. Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021 02 02; 6(1):48. PMID: 33531462.
      Citations: 18     Translation:HumansPHPublic Health
    5. Milewska A, Chi Y, Szczepanski A, Barreto-Duran E, Dabrowska A, Botwina P, Obloza M, Liu K, Liu D, Guo X, Ge Y, Li J, Cui L, Ochman M, Urlik M, Rodziewicz-Motowidlo S, Zhu F, Szczubialka K, Nowakowska M, Pyrc K. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. J Virol. 2021 01 28; 95(4). PMID: 33219167.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192. PMID: 33217362.
      Citations: 278     Fields:    Translation:HumansPHPublic HealthCTClinical Trials